Actively Recruiting
Open-label Randomized Study Comparing Zanidatamab Plus Standard Chemotherapy With or Without PD-1L1 Inhibitors Versus Standard Chemotherapy Alone for Advanced HER2-positive Biliary Tract Cancer
Led by Jazz Pharmaceuticals · Updated on 2026-10-28
286
Participants Needed
185
Research Sites
69 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the use of Zanidatamab combined with standard chemotherapy drugs Cisplatin and Gemcitabine, with or without an additional immune therapy drug chosen by the doctor, for adults with HER2-positive biliary tract cancer. This study aims to assess the effectiveness and safety of adding Zanidatamab to the current standard treatment for this advanced cancer type. Participants will be randomly assigned to receive either Zanidatamab plus Cisplatin and Gemcitabine with or without a PD-1L1 inhibitor either Durvalumab or Pembrolizumab or the standard treatment of Cisplatin and Gemcitabine with or without the same immune therapy drugs. All medications are given through intravenous infusions. The study treatment continues under medical supervision and may vary according to local drug approvals. During the trial, participants will have regular assessments including tumor evaluations to measure progression-free survival and overall survival, along with monitoring treatment response and side effects. Patient-reported outcomes on physical functioning and symptom severity will also be collected. The study may last up to several years, with continuous safety monitoring and follow-up visits to evaluate long-term effects and treatment impact.
CONDITIONS
Brief Title
Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer
Research Team
C
Clinical Trial Disclosure & Transparency
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here